Orion Corporation

Aurigene Discovery Technologies Limited

Ravi Kotrabasaiah Ujjinamatada

Gerd Wohlfahrt

Subhendu Mukherjee

Tero Linnanen

Srinivas Nanduri

Srinivasan Rajagopalan

Susanta Samajdar

Chetan Pandit

Chandrasekhar Abbineni

Prasad Appukuttan

Karthikeyan Narasingapuram Arumugam

Shyla George

The present invention provides substituted tetrahydroquinolinone and related compounds of formula (I), which are therapeutically useful as modulators of Retinoic acid receptor-related orphan receptors (RORs), more particularly as ROR&#x3b3; modulators. These compounds are useful in the treatment and prevention of diseases and/or disorder, in particular their use in diseases and/or disorder mediated by ROR&#x3b3; receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted tetrahydroquinolinone or related compounds of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

Substituted tetrahydroquinolinone compounds as ROR gamma modulators

A compound of formula (I), wherein R, R, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (1) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.

Protein kinase inhibitors

The present invention provides novel spiro[cyclobutane-1,3'-indolin]-2&#x2032;-one derivatives of formula (I)  in which Cy, R, R, R, L, and m have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful as bromodomain inhibitors in the treatment or prevention of diseases or disorders where bromodomain inhibition is desired.

Spiro[cyclobutane-1,3'-indolin]-2&#x2032;-one derivatives as bromodomain inhibitors

A compound of formula (I), wherein R, R, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.

Growing community of inventors

Bengaluru, India

Ravi Kotrabasaiah Ujjinamatada